Godavari Biorefineries Ltd achieved a major milestone in its healthcare innovation journey on Thursday (July 03) by securing a European patent for a novel anticancer molecule.The patent, now validated in key jurisdictions including Spain, the United Kingdom, and under the Unitary Patent system, marks a significant advancement in the company’s presence in the global biotech and pharmaceutical landscape.
The patent falls under the “Anti-Cancer Research Segment” and covers a very potent anticancer compound with proven efficacy on both cancer and cancer stem cells.
Q4 resultsGodavari Biorefineries reported its fourth quarter results on May 26 by posting a 10.37% YoY rise in consolidated net profit to ₹71.93 crore in Q4 FY25. This came despite a 5.80% decline in revenue from operations, which stood at ₹579.50 crore.
The patent falls under the “Anti-Cancer Research Segment” and covers a very potent anticancer compound with proven efficacy on both cancer and cancer stem cells.
Q4 resultsGodavari Biorefineries reported its fourth quarter results on May 26 by posting a 10.37% YoY rise in consolidated net profit to ₹71.93 crore in Q4 FY25. This came despite a 5.80% decline in revenue from operations, which stood at ₹579.50 crore.
Profit before tax (PBT) rose 5.23% YoY to ₹95.74 crore, while EBITDA dipped slightly by 2.17% to ₹121.7 crore. However, the EBITDA margin improved to 21%, up from 20.2% a year ago, helped by a better product mix and cost efficiencies.
On a full-year basis, the company swung to a net loss of ₹23.41 crore for the year ended March 2025, compared to a net profit of ₹12.30 crore in the previous fiscal. Despite the bottom-line pressure, revenue from operations increased 10.88% YoY to ₹1,870.25 crore, up from ₹1,686.67 crore a year earlier, indicating continued growth in top-line performance.
Also Read: AWL Agri Business Q1 Update: Revenue jumps 21% despite 4% decline in volumes
